Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Tumor, KRAS Mutation Clear all
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06720987
View directory record Official record
Conditions
KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
Interventions
KQB365, Cetuximab, KQB198
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Recruiting Phase 1 Interventional

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT07300150
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
Interventions
PT0511, Cetuximab
Drug
Lead sponsor
PAQ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • San Antonio, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Suspended Phase 1 Interventional

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167
View directory record Official record
Conditions
Solid Tumors
Interventions
JSI-1187, Dabrafenib
Drug
Lead sponsor
JS InnoPharm, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jun 10, 2026, 1:59 PM EDT
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jun 10, 2026, 1:59 PM EDT
Recruiting Phase 1 Interventional

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NCT07349537
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors
Interventions
RMC-5127, daraxonrasib, cetuximab
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Elironrasib, Daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
21
States / cities
Duarte, California • Orange, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Terminated Phase 1 Interventional

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

NCT06270082
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Interventions
IK-595
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Duarte, California • Orange, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 10, 2026, 1:59 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

NCT05162443
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm
Interventions
adagrasib (MRTX849)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
U.S. locations
11
States / cities
San Francisco, California • Santa Rosa, California • Hartford, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jun 10, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

NCT06056024
View directory record Official record
Conditions
Solid Tumor, KRAS Mutation
Interventions
BI 3706674
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

NCT04330664
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions
MRTX849, TNO155
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jun 10, 2026, 1:59 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

NCT04111458
View directory record Official record
Conditions
Solid Tumors, KRAS Mutation; SOS1
Interventions
BI 1701963, Trametinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Charlotte, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

NCT04165031
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
Interventions
LY3499446, Abemaciclib, Cetuximab, Erlotinib, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jun 10, 2026, 1:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT03785249
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions
MRTX849, Pembrolizumab, Cetuximab, Afatinib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
221
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 10, 2026, 1:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

NCT06973564
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
JAB-23E73
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Not listed Phase 1Phase 2 Interventional

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

NCT05119933
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
YL-15293
Drug
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Whittier, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Jun 10, 2026, 1:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Interventions
ELI-002 7P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT06835569
View directory record Official record
Conditions
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
Interventions
ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, mFOLFIRINOX, GnP, Midazolam
Drug
Lead sponsor
Alterome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

NCT07023731
View directory record Official record
Conditions
KRAS G12D Mutation, Advanced Solid Cancer
Interventions
ARV-806
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

NCT05578092
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
Interventions
MRTX0902, MRTX849
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
17
States / cities
New Haven, Connecticut • Newark, Delaware • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Terminated Phase 1 Interventional

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

NCT05375084
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Solid Tumor
Interventions
BBP-398 with nivolumab
Drug
Lead sponsor
Navire Pharma Inc., a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Springdale, Arkansas • La Jolla, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jun 10, 2026, 1:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

NCT03600883
View directory record Official record
Conditions
KRAS p.G12C Mutant Advanced Solid Tumors
Interventions
sotorasib, Anti PD-1/L1, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
39
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

NCT04973163
View directory record Official record
Conditions
Solid Tumors, KRAS Mutation
Interventions
BI 1823911, BI 1701963, Midazolam
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jun 10, 2026, 1:59 PM EDT
Active, not recruiting Phase 1 Interventional

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

NCT05163028
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Interventions
HBI-2376
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Duarte, California • Encinitas, California • Fullerton, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jun 10, 2026, 1:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

NCT07148128
View directory record Official record
Conditions
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
Interventions
WEF-001
Drug
Lead sponsor
Auricula Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 10, 2026, 1:59 PM EDT